


Patricia Mazón, Rafael Chinchilla, Carmen Nájera,*
 Gabriela Guillena, Rob Kreiter, Robertus J. M. Klein Gebbink
 and Gerard van Koten*

Tetrahedron: Asymmetry 13 (2002) 2181



N-[3,5-Di(benzyloxy)benzyl]cinchonidinium bromide


Mp 215°C

$[\alpha]_D^{25} = -160$ (*c* 1, CHCl₃)

Source of chirality: (-)-cinchonidine

Patricia Mazón, Rafael Chinchilla, Carmen Nájera,*
 Gabriela Guillena, Rob Kreiter, Robertus J. M. Klein Gebbink
 and Gerard van Koten*

Tetrahedron: Asymmetry 13 (2002) 2181



O(9)-Allyl-*N*-(3,5-dimethoxybenzyl)cinchonidinium bromide


Mp 164°C

$[\alpha]_D^{25} = -136$ (*c* 1, CHCl₃)

Source of chirality: (-)-cinchonidine

Patricia Mazón, Rafael Chinchilla, Carmen Nájera,*
 Gabriela Guillena, Rob Kreiter, Robertus J. M. Klein Gebbink
 and Gerard van Koten*

Tetrahedron: Asymmetry 13 (2002) 2181



O(9)-Benzyl-*N*-(3,5-dimethoxybenzyl)cinchonidinium bromide


Mp 154°C

$[\alpha]_D^{25} = -60$ (*c* 1, CHCl₃)

Source of chirality: (-)-cinchonidine

Patricia Mazón, Rafael Chinchilla, Carmen Nájera,*
 Gabriela Guillena, Rob Kreiter, Robertus J. M. Klein Gebbink
 and Gerard van Koten*

Tetrahedron: Asymmetry 13 (2002) 2181




N-(3,5-Dimethoxybenzyl)cinchonidinium bromide

Mp 203°C


$[\alpha]_D^{25} = -201$ (*c* 1, CHCl₃)

Source of chirality: (-)-cinchonidine




$C_{28}H_{21}As$
4,5-Dihydro-4-phenyl-3*H*-dinaphtho[2,1-*c*:1',2'-*e*]arsepin

$M_p = 150\text{--}155^\circ C$ (CH_2Cl_2 -hexane)
 $[\alpha]_D^{20} = -213.2$ (c 1.43, CHCl_3)
Source of chirality: (*S*)-(-)-1,1'-bi-2-naphthol
Absolute configuration: *S*




$C_{31}H_{26}AsBrO_2$
4-Carbomethoxymethyl-4,5-dihydro-4-phenyl-3*H*-dinaphtho[2,1-*c*:1',2'-*e*]arsepinium bromide

$M_p = 189\text{--}190^\circ C$ (MeOH)
 $[\alpha]_D^{20} = -79.5$ (c 0.40, MeOH)
Source of chirality: (*S*)-(-)-1,1'-bi-2-naphthol
Absolute configuration: *S*




$C_{15}H_{18}O_2$
Methyl (4-phenylcyclohexylidene)acetate

$E_e = 25.4\%$
 $[\alpha]_D^{20} = -32.5$ (c 0.71, CHCl_3)
Source of chirality: asymmetric synthesis (Wittig)
Absolute configuration: *R*



$C_{10}H_{16}O_2$
Methyl (4-methylcyclohexylidene)acetate


$E_e = 33.5\%$
 $[\alpha]_D^{20} = -21.1$ (c 0.64, CHCl_3)
Source of chirality: asymmetric synthesis (Wittig)
Absolute configuration: *R*

 $C_{13}H_{22}O_2$ Methyl (4-*tert*-butylcyclohexylidene)acetate

Ee = 40.0%

 $[\alpha]_D^{20} = -26.5$ (*c* 0.51, CHCl₃)

Source of chirality: asymmetric synthesis (Wittig)


Absolute configuration: *R* $C_{14}H_{24}O_2$

Methyl [4-(1',1'-dimethylpropyl)cyclohexylidene]acetate

Ee = 39.2%

 $[\alpha]_D^{20} = -24.7$ (*c* 1.21, CHCl₃)


Source of chirality: asymmetric synthesis (Wittig)

Absolute configuration: *R* $C_{17}H_{24}O_2$ (2*S*,2'*RS*)-2-(1,1,2,3,3-Pentamethylindan-5-yl)propionic acid

E.e. = 89%

 $[\alpha]_D^{25} = +36.4$ (*c* 1.0, CHCl₃)

Source of chirality: asymmetric hydrogenation


Absolute configuration: 2*S*,2'*RS* $C_{10}H_{19}NO_5$ (R)-(+)-3-*O*-Acetyl-2-*N*-(*tert*-butoxycarbonyl)serinol

E.e. >99% (by HPLC)

 $[\alpha]_D^{30} = +3.5$ (*c* 0.56, CHCl₃)

Source of chirality: lipase-catalysed kinetic resolution

Absolute configuration: *R*




C₁₁H₁₃NO₃
(R)-(+)-4-Benzyl-2-oxazolidinone

E.e. >99% (by HPLC)

[α]_D³⁰ = +25.0 (*c* 0.08, CHCl₃)

Source of chirality: lipase-catalysed kinetic resolution

Absolute configuration: *R*




C₆H₉NO₄
(S)-(−)-4-Acetoxy-2-oxazolidinone

E.e. >98% (by HPLC)

[α]_D³⁰ = −40.7 (*c* 1.35, CHCl₃)

Source of chirality: lipase-catalysed kinetic resolution

Absolute configuration: *S*




C₄₄H₅₉NO₁₇

Methyl (2,3,4-tri-*O*-acetyl- α -L-rhamnopyranosyl)-(1→3)-(2-acetamido-2-deoxy-4,6-*O*-isopropylidene- β -D-glucopyranosyl)-(1→2)-3,4-di-*O*-benzyl- α -L-rhamnopyranoside

[α]_D = −15 (*c* 1.0, chloroform)

Source of chirality: L-rhamnose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy




C₄₁H₅₅NO₁₇

Methyl (2,3,4-tri-*O*-acetyl- α -L-rhamnopyranosyl)-(1→3)-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1→2)-3,4-di-*O*-benzyl- α -L-rhamnopyranoside

[α]_D = +4 (*c* 1.0, chloroform)


Source of chirality: L-rhamnose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy

 $C_{35}H_{49}NO_{14}$ Methyl α -L-rhamnopyranosyl-(1 \rightarrow 3)-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-3,4-di-O-benzyl- α -L-rhamnopyranoside $[\alpha]_D = -25$ (*c* 1.0, chloroform)


Source of chirality: L-rhamnose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy

 $C_{21}H_{37}NO_{14}$ Methyl α -L-rhamnopyranosyl-(1 \rightarrow 3)-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)- α -L-rhamnopyranoside $[\alpha]_D = -51$ (*c* 1.0, water)


Source of chirality: L-rhamnose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy

 $C_{86}H_{95}NO_{21}$ Methyl (2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 4)-(2,3-di-O-benzoyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-(2-acetamido-2-deoxy-4,6-O-isopropylidene- β -D-glucopyranosyl)-(1 \rightarrow 2)-3,4-di-O-benzyl- α -L-rhamnopyranoside $[\alpha]_D = +85$ (*c* 1.0, chloroform)


Source of chirality: L-rhamnose, D-glucose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy

 $C_{83}H_{91}NO_{21}$ Methyl (2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 4)-(2,3-di-O-benzoyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-3,4-di-O-benzyl- α -L-rhamnopyranoside $[\alpha]_D = +79$ (*c* 1.0, chloroform)

Source of chirality: L-rhamnose, D-glucose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy




Methyl (2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 4)- α -L-rhamnopyranosyl-(1 \rightarrow 3)-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-3,4-di-*O*-benzyl- α -L-rhamnopyranoside

$[\alpha]_D = +38$ (*c* 1.0, chloroform)

Source of chirality: L-rhamnose, D-glucose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy




Methyl α -D-glucopyranosyl-(1 \rightarrow 4)- α -L-rhamnopyranosyl-(1 \rightarrow 3)-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)- α -L-rhamnopyranoside

$[\alpha]_D = +3$ (*c* 1.0, water)

Source of chirality: L-rhamnose, D-glucose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy




Methyl (2-*O*-acetyl-3,4-di-*O*-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)]-(2-*O*-benzoyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-(2-acetamido-2-deoxy-4,6-*O*-isopropylidene- β -D-glucopyranosyl)-(1 \rightarrow 2)-3,4-di-*O*-benzyl- α -L-rhamnopyranoside

$[\alpha]_D = +26$ (*c* 1.0, chloroform)

Source of chirality: L-rhamnose, D-glucose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy





Methyl (3,4-di-*O*-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)]- α -L-rhamnopyranosyl-(1 \rightarrow 3)-(2-acetamido-2-deoxy-4,6-*O*-isopropylidene- β -D-glucopyranosyl)-(1 \rightarrow 2)-3,4-di-*O*-benzyl- α -L-rhamnopyranoside

$[\alpha]_D = +21$ (*c* 1.0, chloroform)

Source of chirality: L-rhamnose, D-glucose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy





Methyl (3,4-di-O-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl-(1 \rightarrow 4)]- α -L-rhamnopyranosyl-(1 \rightarrow 3)-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)-3,4-di-O-benzyl- α -L-rhamnopyranoside

$[\alpha]_D = +22$ (*c* 1.0, chloroform)

Source of chirality: L-rhamnose, D-glucose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy





Methyl α -L-rhamnopyranosyl-(1 \rightarrow 3)-[α -D-glucopyranosyl-(1 \rightarrow 4)]- α -L-rhamnopyranosyl-(1 \rightarrow 3)-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 2)- α -L-rhamnopyranoside

$[\alpha]_D = -12$ (*c* 1.0, water)

Source of chirality: L-rhamnose, D-glucose, D-glucosamine, glycosylation

Absolute configuration of the anomeric centers assigned by NMR spectroscopy





4-(3'-O-Benzyl-1',2'-O-isopropylidene- α -D-xylo-tetros-4-yl)-2-phenyl-(3a*S*,4*R*,7a*S*)-tetrahydro-*iso*-indole-1,3-dione

$[\alpha]_D = -4.2$ (*c* 1.5, CHCl₃)

Source of chirality: chiral pool

Absolute configuration: 3a*S*,4*R*,7a*S*




4-(3'-O-Benzyl-1',2'-O-isopropylidene- α -D-xylo-tetros-4-yl)-2-phenyl-(3a*R*,4*S*,7a*R*)-tetrahydro-*iso*-indole-1,3-dione

$[\alpha]_D = -40.3$ (*c* 1.3, CHCl₃)

Source of chirality: chiral pool

Absolute configuration: 3a*R*,4*S*,7a*R*




4-(Methyl 2',3'-di-O-benzyl- β -L-arabino-tetrosid-4-yl)-2-phenyl-(3aR,4S,7aR)-tetrahydro-iso-indole-1,3-dione

$[\alpha]_D$ 82.2 (*c* 1.4, CHCl₃)

Source of chirality: chiral pool

Absolute configuration: 3aR,4S,7aR




4-(Methyl 2',3'-di-O-benzyl- β -L-arabino-tetrosid-4-yl)-2-phenyl-(3aS,4R,7aS)-tetrahydro-iso-indole-1,3-dione

$[\alpha]_D$ -106.0 (*c* 1.0, CHCl₃)

Source of chirality: chiral pool

Absolute configuration: 3aS,4R,7aS




4-(Acetoxyethyl)-2-phenyl-(3aS,4R,7aS)-tetrahydro-iso-indole-1,3-dione

$[\alpha]_D$ -12.1 (*c* 3.6, CHCl₃)

Source of chirality: chiral pool

Absolute configuration: 3aS,4R,7aS




4-[1',2'(S)-Di-O-benzyloxyethane-2'-yl]-2-phenyl-(3aS,4R,7aS)-tetrahydro-iso-indole-1,3-dione

$[\alpha]_D$ -87.3 (*c* 2.1, CHCl₃)

Source of chirality: chiral pool

Absolute configuration: 2'S,3aS,4R,7aS





4-[1',2'-(S)-Di-O-benzylxyethane-2'-yl]-2-phenyl-(3aR,4S,7aR)-tetrahydro-*iso*-indole-1,3-dione

$[\alpha]_D^{20} +11.5$ (*c* 2.1, CHCl₃)

Source of chirality: chiral pool


Absolute configuration: 2'S,3aR,4S,7aR



(2*R*,5*S*)-2-Trichloromethyl-1-aza-3-oxobicyclo-[3.3.0]-octan-4,8-dione

Mp=229.2°C


$[\alpha]_D^{22} = +43.5$ (*c* 2, C₆H₆)



(2*R*,5*S*)-2-Trichloromethyl-1-aza-3-oxobicyclo-[3.3.0]-octan-4-one

Mp=107.6°C (from EtOH)


$[\alpha]_D^{22} = +32.7$ (*c* 2, C₆H₆)




(5*S*)-(Pyrrolidine-1-carbonyl)-pyrrolidin-2-one

Mp=114.3°C (from EtOAc)


$[\alpha]_D^{20} = -43.6$ (*c* 2, H₂O)

 $C_{10}H_{16}N_2O_2$


(5S)-(Piperidine-1-carbonyl)-pyrrolidin-2-one

 $M_p = 58^\circ C$ (from EtOAc) $[\alpha]_D^{20} = -46.7$ (*c* 2, H₂O) $C_{12}H_{14}N_2O_2$

5-oxo-Pyrrolidine-(2S)-carboxylic acid benzylamide


 $M_p = 138.3^\circ C$ (from EtOAc) $[\alpha]_D^{22} = -29.6$ (*c* 2, H₂O) $[\alpha]_D^{21} = -79$ (*c* 2, EtOH) $C_{10}H_{16}N_2O_2$

(S)-2-(Pyrrolidine-1-carbonyl)-pyrrolidine-1-carbaldehyde

 $C_{13}H_{16}N_2O_2$


5-oxo-Pyrrolidine-(2S)-carboxylic acid-(R)-phenylethylamide

 $M_p = 153^\circ C$ (from EtOAc) $[\alpha]_D^{20} = +103.5$ (*c* 1.7, H₂O)




$C_{11}H_{18}N_2O_2$
 (S) -2-(Piperidine-1-carbonyl)-pyrrolidine-1-carbaldehyde

$[\alpha]_D^{21} = -69.5$ (*c* 1.05, EtOH)




$C_9H_{18}N_2$
 (S) -(1-Pyrrolidinylmethyl)pyrrolidine

$B_p = 30^\circ C / 7.6 \times 10^{-2}$ mmHg
 $[\alpha]_D^{20} = +8.9$ (*c* 2.4, EtOH)




$C_{10}H_{20}N_2$
 (S) -2-(1-Piperidinylmethyl)pyrrolidine

Kugelrohr distillation, $110^\circ C / 7.6$ mmHg
 $[\alpha]_D^{21} = +15$ (*c* 7.75, EtOH)




$C_{12}H_{18}N_2$
 (S) -2-(1-Benzylmethyl)pyrrolidine

Kugelrohr distillation, bp: $120^\circ C / 5 \times 10^{-2}$ mmHg
 $[\alpha]_D^{20} = +15.6$ (*c* 1.01, EtOH)




C₁₃H₂₀N₂
(S)-2-((1R)-Phenylethylmethyl)pyrrolidine

Kugelrohr distillation, bp: 113°C/7.6×10⁻² mmHg
[α]_D²⁰ = +54.4 (c 1.02, EtOH)




C₁₀H₂₀N₂
(S)-N-Methyl-2-(1-pyrrolidinomethyl)pyrrolidine

Bp = 50°C/0.7 mmHg
[α]_D²⁰ = -83.6 (c 0.63, EtOH)




C₁₁H₂₂N₂
(S)-N-Methyl-2-(1-piperidinylmethyl)pyrrolidine

Bp = 55°C/0.6 mmHg
[α]_D²⁰ = -65.1 (c 0.55, EtOH)



C₄₄H₄₄N₂O₆
(R,R)-N-Propyl-N'-3(1-pyrenyl)propyl-O,O'-bis(dimethylbenzoyl)tartaramide

[α]_D⁵⁸⁹ = -69 (c 0.26, dioxane)
Source of chirality: (R,R)-tartaric acid




trans-($\alpha R,1R,2R$)-2-Benzoylamino-1-(1-phenylethylamino)cyclohexanecarboxamide

$[\alpha]_D^{20} = -4.3$ (*c* 1.02, methanol)

Source of chirality: asymmetric synthesis

Absolute configuration: $\alpha R,1R,2R$




trans-($\alpha R,1S,2S$)-2-Benzoylamino-1-(1-phenylethylamino)cyclohexanecarboxamide

$[\alpha]_D^{20} = +51.2$ (*c* 1.01, methanol)

Source of chirality: asymmetric synthesis

Absolute configuration: $\alpha R,1S,2S$




trans-($\alpha R,1R,2R$)-2-p-Nitrobenzoylamino-1-(1-phenylethylamino)cyclohexanecarboxamide

$[\alpha]_D^{20} = -3.4$ (*c* 0.93, methanol)

Source of chirality: asymmetric synthesis

Absolute configuration: $\alpha R,1R,2R$




trans-($\alpha R,1S,2S$)-2-p-Nitrobenzoylamino-1-(1-phenylethylamino)cyclohexanecarboxamide

$[\alpha]_D^{20} = +50.0$ (*c* 1.12, methanol)

Source of chirality: asymmetric synthesis

Absolute configuration: $\alpha R,1S,2S$




C₁₄H₁₉N₃O₂

trans-(1*R*,2*R*)-1-Amino-2-benzoylaminocyclohexanecarboxamide

[α]_D²⁰ = +15.3 (*c* 1.09, methanol)

Source of chirality: asymmetric synthesis

Absolute configuration: 1*R*,2*R*




C₁₄H₁₈N₄O₄

trans-(1*S*,2*S*)-1-Amino-2-*p*-nitrobenzoylaminocyclohexanecarboxamide

[α]_D²⁰ = -17.1 (*c* 0.97, methanol)

Source of chirality: asymmetric synthesis

Absolute configuration: 1*S*,2*S*




C₁₄H₁₉N₃O₂·HCl

cis-(1*S*,2*R*)-1-Amino-2-benzoylaminocyclohexanecarboxamide hydrochloride

[α]_D²⁰ = +7.4 (*c* 0.76, methanol)

Source of chirality: asymmetric synthesis

Absolute configuration: 1*S*,2*R*




C₁₄H₁₈N₂O₃·HCl

cis-(1*S*,2*R*)-1-Amino-2-benzoylaminocyclohexanecarboxylic acid hydrochloride

[α]_D²⁰ = +10.4 (*c* 1.61, methanol)

Source of chirality: asymmetric synthesis

Absolute configuration: 1*S*,2*R*




C₇H₁₄N₂O₂

trans-(1*S*,2*S*)-1,2-Diaminocyclohexanecarboxylic acid

[α]_D²⁰ = -8.0 (*c* 1.01, H₂O)

Source of chirality: asymmetric synthesis

Absolute configuration: 1*S*,2*S*




C₂₈H₂₈N₂O₂

(1*S*,2*S*,5*S*,6*S*)-2,6-Di-(quinolin-2-ylmethyl)-bicyclo[3.3.0]octan-2,6-diol

[α]_D²⁰ = +53.1 (*c* 1.40, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: 1*S*,2*S*,5*S*,6*S*




C₁₈H₁₉NO₂

(1*S*,5*S*,6*S*)-6-Hydroxy-6-(quinolin-2-ylmethyl)-bicyclo[3.3.0]octan-2-one

[α]_D²⁰ = +147.6 (*c* 0.65, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: 1*S*,5*S*,6*S*




C₁₇H₂₃NO₃

(1*R*,5*R*,6*R*)-6-Hydroxy-6-(methylpyridin-2-ylmethyl)-bicyclo[3.3.0]octan-2-one ethylene ketal


[α]_D²⁰ = -26.2 (*c* 1.10, CHCl₃)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R*,5*R*,6*R*

 $C_{20}H_{23}NO_3$ (1*R*,5*R*,6*R*)-6-Hydroxy-6-(quinolin-2-ylmethyl)-bicyclo[3.3.0]octan-2-one ethylene ketal $[\alpha]_D^{20} = -14.6$ (*c* 0.85, CHCl₃)


Source of chirality: enzymatic resolution

Absolute configuration: 1*R*,5*R*,6*R* $C_{15}H_{19}NO_2$ (1*R*,5*R*,6*R*)-6-Hydroxy-6-(methylpyridin-2-ylmethyl)-bicyclo[3.3.0]octan-2-one $[\alpha]_D^{20} = -145.7$ (*c* 2.45, CHCl₃)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R*,5*R*,6*R* $C_{18}H_{19}NO_2$ (1*R*,5*R*,6*R*)-6-Hydroxy-6-(quinolin-2-ylmethyl)-bicyclo[3.3.0]octan-2-one $[\alpha]_D^{20} = -145.6$ (*c* 2.45, CHCl₃)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R*,5*R*,6*R* $C_8H_{19}NO$

(R)-3-Aminooctanol



 $[\alpha]_D^{20} = -14.4$ (*c* 1.3, CHCl₃)Source of chirality: lithium (*R*)- α -methylbenzylamideAbsolute configuration: *R*


 $C_{23}H_{37}NO_4$

(E)-3-(N-(R)-1'-Hydroxy-3'-octyl)amino-1-benzoylethoxycarbonylhexenoic acid ethyl ester

 $[\alpha]_D^{20} = +8.9$ (*c* 2.6, CHCl₃)Source of chirality: lithium (R)- α -methylbenzylamideAbsolute configuration: *R* $C_{23}H_{35}NO_3$

(R)-2-Pentyl-5-ethoxycarbonyl-6-(3-benzyloxypropyl)-1,2,3,4-tetrahydropyridine

 $[\alpha]_D^{20} = +86.5$ (*c* 1.23, CHCl₃)Source of chirality: (R)- α -methylbenzylamideAbsolute configuration: *R* $C_{16}H_{31}NO_3$ (1*S*,2*S*,6*R*)-1-(3-Hydroxypropyl)-2-ethoxycarbonyl-6-pentyl-piperidine $[\alpha]_D^{20} = -11$ (*c* 0.97, CHCl₃)Source of chirality: (R)- α -methylbenzylamideAbsolute configuration: 1*S*,2*S*,6*R* $C_{16}H_{29}NO_2$ (5*R*,8*S*,8*a**S*)-5-Pentyloctahydroindolizidine-8-carboxylic acid, ethyl ester $[\alpha]_D^{20} = -31.5$ (*c* 0.25, CHCl₃)Source of chirality: lithium (R)- α -methylbenzylamideAbsolute configuration: 5*R*,8*S*,8*a**S*




$C_{15}H_{18}Br_2N_2O_2$
(2S)-N-[(E)-2(2,4-Dibromo-5-methoxyphenyl)ethanyl]-1-methyl-2-pyrrolinecarboxamide

Ee = 100%

$[\alpha]_D^{25} = -46$ (*c*, CH_2Cl_2)

Source of chirality: chiral starting material

Absolute configuration: 2*S*




$C_{15}H_{18}Br_3N_2O_2$
(2S)-N-[(E)-2(2,4,6-Tribromo-5-methoxyphenyl)ethanyl]-1-methyl-2-pyrrolinecarboxamide

Ee = 100%

$[\alpha]_D^{25} = -9.8$ (*c*, CH_2Cl_2)

Source of chirality: chiral starting material

Absolute configuration: 2*S*



$C_{17}H_{26}NO_4P$
Diethyl 1-[formyl(1'-methylbenzyl)amino]-2-methyl-cyclopropanephosphonate


E.e. >99% (by GC on chiral column)

$[\alpha]_D^{20} = -14.3$ (*c* 0.8, $CHCl_3$)

^{31}P NMR ($CDCl_3$): $\delta = 24.30$ ppm

Source of chirality: (*S*)-(1-phenyl)ethylamine

Absolute configuration: (1*S*,2*S*,1'*S*)



$C_{17}H_{26}NO_4P$
Diethyl 1-[formyl(1'-methylbenzyl)amino]-2-methyl-cyclopropanephosphonate


E.e. >98% (by GC on chiral column)

$[\alpha]_D^{20} = +104.7$ (*c* 1, $CHCl_3$)

^{31}P NMR ($CDCl_3$): $\delta = 24.78$ ppm



Source of chirality: (*S*)-(1-phenyl)ethylamine

Absolute configuration: (1*R*,2*R*,1'*S*)




Diisopropyl 1-[formyl(1'-methylbenzyl)amino]-2-methyl-cyclopropanephosphonate

E.e. >99% (by GC on chiral column)

 $[\alpha]_D^{20} -14.5$ (*c* 1, CHCl₃)³¹P NMR (CDCl₃): $\delta = 21.98$ ppmSource of chirality: (*S*)-(1-phenyl)ethylamineAbsolute configuration: (1*S*,2*S*,1'*S*)


Diisopropyl 1-[formyl(1'-methylbenzyl)amino]-2-methyl-cyclopropanephosphonate

E.e. >98% (by GC on chiral column)

 $[\alpha]_D^{20} +118.7$ (*c* 1, CHCl₃)³¹P NMR (CDCl₃): $\delta = 22.50$ ppmSource of chirality: (*S*)-(1-phenyl)ethylamineAbsolute configuration: (1*R*,2*R*,1'*S*)

Diethyl 1-amino-2-methyl-cyclopropanephosphonate


E.e. >99% (by GC on chiral column)

 $[\alpha]_D^{20} +24.4$ (*c* 1, CHCl₃)³¹P NMR (CDCl₃): $\delta = 29.28$ ppmSource of chirality: (*S*)-(1-phenyl)ethylamine for the precursorAbsolute configuration: (1*S*,2*S*) by comparison with the literature

Diisopropyl 1-amino-2-methyl-cyclopropanephosphonate


E.e. >99% (by GC on chiral column)

 $[\alpha]_D^{20} +19.5$ (*c* 1.1, CHCl₃)³¹P NMR (CDCl₃): $\delta = 27.72$ ppmSource of chirality: (*S*)-(1-phenyl)ethylamine for the precursorAbsolute configuration: (1*S*,2*S*) by transformation into known acid




1-Amino-2-methyl-cyclopropanephosphonate

E.e. >99% (by GC on chiral column)

 $[\alpha]_D^{20} +45.2$ (*c* 0.2, H₂O)³¹P NMR (D₂O): $\delta = 13.36$ ppmSource of chirality: (*S*)-(1-phenyl)ethylamine for the precursorRelative configuration: (1*S*,2*S*) by comparison with the literature


(R)-1-(1-Naphthyl)ethylamine

E.e. = 97.0%

 $[\alpha]_D^{20} = +53.5$ (*c* 2, ethanol)Source of chirality: chemical resolution with 3-carboxy-2-naphthoate of (*R*)-isopropylidene glycerolAbsolute configuration: *R*

(S)-1-Phenyl-2-propylamine


E.e. = 78.0%

 $[\alpha]_D^{20} = +30.5$ (*c* 1.8, benzene)Source of chirality: chemical resolution with 3-carboxy-2-naphthoate of (*R*)-isopropylidene glycerolAbsolute configuration: *S*

(S)-1-(4-Bromophenyl)ethylamine

E.e. >99.5%

 $[\alpha]_D^{20} = -21.0$ (*c* 2.8, methanol)Source of chirality: chemical resolution with 3-carboxy-2-naphthoate of (*R*)-isopropylidene glycerolAbsolute configuration: *S*




C₈H₁₇N
(S)-1-Cyclohexylethylamine

E.e. = 94.1%

[α]_D²⁰ = +3.8 (neat)

Source of chirality: chemical resolution with
3-carboxy-2-naphthoate of (*R*)-isopropylidene glycerol
Absolute configuration: *S*




C₁₆H₂₂N₄O₈S
(*R*)-1-(4-Nitrophenyl)ethylamine sulphate

E.e. = 98.9%

[α]_D²⁰ = +6.6 (c 1.07, 0.05 M NaOH)

Source of chirality: chemical resolution with
3-carboxy-2-naphthoate of (*R*)-isopropylidene glycerol
Absolute configuration: *R*




C₄H₁₂ClN
(*S*)-2-Butylamine hydrochloride

E.e. = 77.9%

[α]_D²⁰ = -2.6 (c 1.0, EtOH)

Source of chirality: chemical resolution with
3-carboxy-2-naphthoate of (*R*)-isopropylidene glycerol
Absolute configuration: *S*




C₁₂H₁₃N
(*R*)-1-(2-Naphthyl)ethylamine

E.e. = 94.4%

[α]_D²⁵ = +19.9 (c 2.5, ethanol)

Source of chirality: chemical resolution with
3-carboxy-2-naphthoate of (*R*)-isopropylidene glycerol
Absolute configuration: *R*




C₁₂H₁₂F₂O₂
(S)-4-Acetoxy-3,3-difluoro-4-phenylbut-1-ene

Ee = 84%

[α]_D²³ = +52.2 (c 1.45, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *S*




C₁₃H₁₁F₂NO₂
(S)-4-Acetoxy-4-(*p*-cyanophenyl)-3,3-difluorobut-1-ene

Ee = 97%

[α]_D³⁰ = +59.2 (c 1.09, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *S*




C₁₃H₁₄F₂O₃
(S)-4-Acetoxy-3,3-difluoro-4-(*p*-methoxyphenyl)but-1-ene

Ee = 90%

[α]_D²³ = +71.3 (c 1.14, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *S*



C₁₂H₁₂F₂O₂
(*R*)-2,2-Difluoro-1-phenylbut-3-en-1-ol

Ee = 79%

[α]_D²³ = -14.7 (c 1.13, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *R*

Masayuki Kirihara,* Masashi Kawasaki, Hiroki Katsumata,
Hiroko Kakuda, Motoo Shiro and Shigeki Kawabata

Tetrahedron: Asymmetry 13 (2002) 2283



C₁₁H₉F₂NO

(R)-1-(*p*-Cyanophenyl)-2,2-difluorobut-3-en-1-ol

Ee = 88%


[α]_D³¹ = -7.5 (*c* 1.07, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *R*

Masayuki Kirihara,* Masashi Kawasaki, Hiroki Katsumata,
Hiroko Kakuda, Motoo Shiro and Shigeki Kawabata

Tetrahedron: Asymmetry 13 (2002) 2283



C₁₅H₂₄F₂O₂

(S)-4-Acetoxy-3,3-difluorotridec-1-ene

Ee = 67%


[α]_D²⁵ = -8.2 (*c* 1.05, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *S*

Masayuki Kirihara,* Masashi Kawasaki, Hiroki Katsumata,
Hiroko Kakuda, Motoo Shiro and Shigeki Kawabata

Tetrahedron: Asymmetry 13 (2002) 2283



C₁₀H₁₆F₂O

(R)-1-Cyclohexyl-2,2-difluorobut-3-en-1-ol

Ee = 95%


[α]_D²³ = +20.5 (*c* 1.09, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *R*

Masayuki Kirihara,* Masashi Kawasaki, Hiroki Katsumata,
Hiroko Kakuda, Motoo Shiro and Shigeki Kawabata

Tetrahedron: Asymmetry 13 (2002) 2283



C₁₃H₂₄F₂O

(R)-3,3-Difluorotridec-1-en-4-ol

Ee = 82%

[α]_D²⁵ = +19.7 (*c* 1.10, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *R*



C₁₀H₉BrF₂O


(R)-1-(*p*-Bromophenyl)-2,2-difluorobut-3-en-1-ol

Ee = 96%

[α]_D²⁴ = -14.3 (*c* 1.13, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *R*



C₁₁H₁₂F₂O₂


(R)-2,2-Difluoro-1-(*p*-methoxyphenyl)but-3-en-1-ol

Ee = 94%

[α]_D²³ = -20.2 (*c* 1.01, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *R*



C₁₂H₁₈F₂O₂


(S)-4-Acetoxy-4-cyclohexyl-3,3-difluorobut-1-ene

Ee = 87%

[α]_D²⁵ = +5.3 (*c* 1.03, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *S*



C₁₂H₁₁BrF₂O₃

(S)-4-Acetoxy-4-(*p*-bromophenyl)-3,3-difluorobut-1-ene

Ee = 97%

[α]_D²² = +53.8 (*c* 1.21, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: *S*